Cleveland Clinic Cancer Center researchers evaluating bortezomib as a possible prophylaxis for graft-versus-host disease (GVHD) in high-risk multiple myeloma unexpectedly found high rates of acute and chronic GVHD in patients participating in the small phase I clinical trial, forcing its discontinuation.
Research Shows Daratumumab’s Effectiveness in AL Amyloidosis
Recent Cleveland Clinic Cancer Center research shows the monoclonal antibody daratumumab is a safe, effective and fast-acting treatment for amyloid light-chain amyloidosis, producing a hematologic response in more than 80% of relapsed/refractory patients in a small cohort study.